Metastatic RCC, Progressing on Multiple Therapies: Case 1 Metastatic RCC, Progressing on Multiple Therapies
Case Presentation
February 2016
70-year old female, presented to her physician with symptoms of nausea, fatigue, and weight loss Abdominal CT showed a 9-cm left renal tumor and a small solitary spot on the liver She was referred to urology and underwent left radical nephrectomy with removal of the liver lesion Post-surgical imaging showed multiple liver lesions She was then referred to medical oncology and was started on sunitinib 50 mg daily on a 4/2 schedule; stable disease was achieved within 6 weeks Moderate fatigue, diarrhea, and increasing severity of handfoot syndrome were managed with treatment interruption and then dose reduction to
June 2016
Four months later the patient reported increasing fatigue, nausea, and weight loss Abdominal CT showed progression of her liver metastasis She was then switched from sunitinib to nivolumab The patient reported that her symptoms had improved Imaging at 8 weeks showed a response in the liver She was maintained on nivolumab without any toxicity
February 2017
Eight months later, the patient complained of fatigue, abdominal discomfort, and weight loss; she subsequently developed back pain CT scan of abdomen and chest showed new liver lesions and progression of previously identified lesions MRI of the spine showed multiple metastatic lesions of the thoracic and lumbar vertebrae, with no evidence of cord compression She sought a second-opinion at an academic center She was subsequently switched to cabozantinib 60 mg Her symptoms subsided within 4 weeks CT and MRI imaging at 8 weeks showed response with improvement of both liver and spine metastases. She was maintained on cabozantinib for approximately 4 months and developed diarrhea and hand-foot skin reaction Her dose of cabozantinib was reduced to 40 mg daily on which she was maintained for 13 months until she developed disease progression At this time the patient is being considered for enrollment into a clinical trial Newsletter Stay up to date on practice-changing data in community practice.
Subscribe
September 28th, 2026 Clinicians weigh RCC immunotherapy choices by risk, metastasis site, and histology, citing durable outcomes with nivo-ipi and favoring TKIs after early progression.
September 24th, 2026 FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.